NewsBenzingaBioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed Benzinga 2026.09.30 20:22 (GMT+0) Open on Benzinga Other news Solana ETFs End a 14-Week Buying Streak With Their Largest Weekly Exit Amazon Eyes $7B AI Startup Deal as It Pushes Into AI Chips - TipRanks.com SOL spot ETFs saw net outflows of $24.8109 million last week Ethereum spot ETFs saw $542 million in net outflows last week, with BlackRock's ETHA leading at $477 million Elon Musk Takes Swipe at Billionaire Mukesh Ambani's 'De Facto' Monopoly in India: 'Absurd Hypocrisy and Hyperbole' on Starlink Competition DATA Network joins Sui and Walrus to scale the supply chain for AI training data
Ethereum spot ETFs saw $542 million in net outflows last week, with BlackRock's ETHA leading at $477 million
Elon Musk Takes Swipe at Billionaire Mukesh Ambani's 'De Facto' Monopoly in India: 'Absurd Hypocrisy and Hyperbole' on Starlink Competition
